Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/30938
Full metadata record
DC FieldValueLanguage
dc.contributor.authorArroyo, Rafael-
dc.contributor.authorPerez-Sempere, Angel-
dc.contributor.authorRuiz-Beato, Elena-
dc.contributor.authorPrefasi, Daniel-
dc.contributor.authorCarreño, Agata-
dc.contributor.authorRoset, Montse-
dc.contributor.authorMaurino, Jorge-
dc.contributor.otherDepartamentos de la UMH::Medicina Clínicaes_ES
dc.date.accessioned2024-02-01T13:07:24Z-
dc.date.available2024-02-01T13:07:24Z-
dc.date.created2017-03-
dc.identifier.citationBMJ Open . 2017 Mar 8;7(3):e014433es_ES
dc.identifier.issn2044-6055-
dc.identifier.urihttps://hdl.handle.net/11000/30938-
dc.description.abstractObjective: To assess patients' preferences for a range of disease-modifying therapy (DMT) attributes in multiple sclerosis (MS). Design: A cross-sectional observational study. Setting: The data reported were from 17 MS units throughout Spain. Participants: Adult patients with relapsing-remitting MS. Main outcome: A conjoint analysis was applied to assess preferences. A total of 221 patients completed a survey with 10 hypothetical DMT profiles developed using an orthogonal design and rating preferences from 1 (most acceptable) to 10 (least acceptable). Medication attributes included preventing relapse, preventing disease progression, side effect risk, route and frequency of administration. Results: Patients placed the greatest relative importance on the side effect risk domain (32.9%), followed by route of administration (26.1%), frequency of administration (22.7%), prevention of disease progression (10.0%) and prevention of relapse (8.3%). These results were independent of the Expanded Disability Status Scale score. The importance assigned to side effect risk was highest for patients with a recent diagnosis. Patients who had previously received more than one DMT gave a higher importance to relapse rate reduction than patients receiving their first DMT. Conclusions: Patient DMT preferences were mainly driven by risk minimisation, route of administration and treatment schedule. The risk-benefit spectrum of available DMT for MS is becoming increasingly complicated. Understanding which treatment characteristics are meaningful to patients may help to tailor information for them and facilitate shared decision-making in clinical practice.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent8es_ES
dc.language.isoenges_ES
dc.publisherBMJes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectconjoint analysises_ES
dc.subjectdisease-modifying therapieses_ES
dc.subjectpatient preferenceses_ES
dc.subjectrating-based experimentes_ES
dc.titleConjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1136/bmjopen-2016-014433es_ES
Appears in Collections:
Artículos Medicina Clínica


Thumbnail

View/Open:
 Conjoint analysis to understand.pdf

1,1 MB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???